BBO-8520的发现:首创新型直接共价双重抑制GTP结合(ON)与GDP结合(OFF)KRASG12C的抑制剂
已获批的KRASG12C抑制剂通过隔离失活GDP结合(OFF)形式而非直接结合抑制活性GTP结合(ON)形式,对活性蛋白无直接靶点覆盖,临床可见适应性耐药与KRASG12C(ON)表达活性增加相关。BBO-8520是首创新型直接双重抑制KRASG12C(ON)和(OFF)形式的小分子共价抑制剂,结合Switch-II/Helix3口袋并共价修饰靶点半胱氨酸,在生长因子激活状态下显示强效信号抑制,体内实现快速靶点结合和信号抑制,在多种模型(包括对KRASG12C(OFF)抑制剂耐药的模型)中产生持久肿瘤消退,正在KRASG12C非小细胞肺癌患者中进行1期临床试验。
要点
- BBO-8520是首创新型直接共价双重抑制KRASG12C(ON)和(OFF)形式的小分子抑制剂。
- BBO-8520结合Switch-II/Helix3口袋并共价修饰靶点半胱氨酸,阻断效应蛋白与KRASG12C(ON)结合。
- BBO-8520在多种模型(包括对KRASG12C(OFF)抑制剂耐药的模型)中产生持久肿瘤消退,正在进行1期临床试验。
核心结论
- BBO-8520是首创新型直接小分子共价双重抑制剂,可结合KRASG12C的活性(ON)和非活性(OFF)构象,提供最佳靶点覆盖并延迟临床中(OFF)抑制剂出现的适应性耐药。
研究设计与样本
- 临床前研究开发BBO-8520并评估其体外和体内活性,BBO-8520正在KRASG12C非小细胞肺癌患者中进行1期临床试验。
主要发现
- 已获批KRASG12C抑制剂通过隔离失活GDP结合(OFF)形式而非直接结合抑制活性GTP结合(ON)形式,对活性蛋白无直接靶点覆盖。
- 临床观察到KRASG12C(OFF)抑制剂适应性耐药与KRASG12C(ON)表达和活性增加相关。
- BBO-8520结合Switch-II/Helix3口袋,共价修饰靶点半胱氨酸,并阻断效应蛋白与KRASG12C(ON)结合。
- BBO-8520在生长因子激活状态下显示强效信号抑制,而当前(OFF)抑制剂在该状态下可测量的活性很少。
- 体内BBO-8520显示快速靶点结合和信号抑制,在多种模型(包括对KRASG12C(OFF)抑制剂耐药的模型)中产生持久肿瘤消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. This approach provides no direct target coverage of the active protein. Expectedly, adaptive resistance to KRASG12C (OFF)-only inhibitors is observed in association with increased expression and activity of KRASG12C(ON). To provide optimal KRASG12C target coverage, we have developed BBO-8520, a first-in-class, direct dual inhibitor of KRASG12C(ON) and (OFF) forms. BBO-8520 binds in the Switch-II/Helix3 pocket, covalently modifies the target cysteine, and disables effector binding to KRASG12C(ON). BBO-8520 exhibits potent signaling inhibition in growth factor-activated states, in which current (OFF)-only inhibitors demonstrate little measurable activity. In vivo, BBO-8520 demonstrates rapid target engagement and inhibition of signaling, resulting in durable tumor regression in multiple models, including those resistant to KRASG12C(OFF)-only inhibitors. BBO-8520 is in phase 1 clinical trials in patients with KRASG12C non-small cell lung cancer. Significance: BBO-8520 is a first-in-class direct, small molecule covalent dual inhibitor that engages KRASG12C in the active (ON) and inactive (OFF) conformations. BBO-8520 represents a novel mechanism of action that allows for optimal target coverage and delays the emergence of adaptive resistance seen with (OFF)-only inhibitors in the clinic. See related commentary by Zhou and Westover, p. 455.
引用
- Maciag AE, Stice JP, Wang B, et al. Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C. Cancer Discov. 2025. PMID: 39642212. doi:10.1158/2159-8290.CD-24-0840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。